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Abstract
Genetic variants contribute to normal variation of iron-related traits and may also cause clinical syndromes of iron deficiency
or excess. Iron overload and deficiency can adversely affect human health. For example, elevated iron storage is associated
with increased diabetes risk, although mechanisms are still being investigated. We conducted the first genome-wide associ-
ation study of serum iron, total iron binding capacity (TIBC), transferrin saturation, and ferritin in a Hispanic/Latino cohort,
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the Hispanic Community Health Study/Study of Latinos (>12 000 participants) and also assessed the generalization of previ-
ously known loci to this population. We then evaluated whether iron-associated variants were associated with diabetes and
glycemic traits. We found evidence for a novel association between TIBC and a variant near the gene for protein phosphatase
1, regulatory subunit 3B (PPP1R3B; rs4841132, b¼0.116, P¼7.44  108). The effect strengthened when iron deficient individ-
uals were excluded (b¼0.121, P¼4.78  109). Ten of sixteen variants previously associated with iron traits generalized to
HCHS/SOL, including variants at the transferrin (TF), hemochromatosis (HFE), fatty acid desaturase 2 (FADS2)/myelin regula-
tory factor (MYRF), transmembrane protease, serine 6 (TMPRSS6), transferrin receptor (TFR2), N-acetyltransferase 2 (arylamine
N-acetyltransferase) (NAT2), ABO blood group (ABO), and GRB2 associated binding protein 3 (GAB3) loci. In examining iron
variant associations with glucose homeostasis, an iron-raising variant of TMPRSS6 was associated with lower HbA1c levels
(P¼8.66  1010). This association was attenuated upon adjustment for iron measures. In contrast, the iron-raising allele of
PPP1R3B was associated with higher levels of fasting glucose (P ¼ 7.70  107) and fasting insulin (P¼4.79  106), but these
associations were not attenuated upon adjustment for TIBC—so iron is not likely a mediator. These results provide new gen-
etic information on iron traits and their connection with glucose homeostasis.
Introduction
Iron is necessary for various metabolic processes, including
oxygen transport and storage, redox reactions, cell signaling
and microbial defense. Absorption, transport and storage of
iron are carefully regulated (reviewed in 1,2), presumably to
avert potential toxic effects of free iron (such as formation of
superoxide radicals and cellular apoptosis). Both iron overload
and iron deficiency can be detrimental to health (1), so iron
homeostasis is essential. Although many factors that take part
in iron homeostasis are known (1,2), mechanisms by which the
body regulates iron stores are still being elucidated (3).
In plasma, ferric iron is normally carried by transferrin (TF),
en route to the TF receptor in organs such as the bone marrow,
liver and spleen. Levels of serum ferritin, a key iron storage pro-
tein in the cytosol, nucleus and mitochondria, correlate with
iron stores under most physiological conditions. Biomarkers of
iron homeostasis, including serum iron, total iron binding cap-
acity (TIBC), transferrin saturation (SAT) and ferritin, are used
clinically to assess iron overload or deficiency. Genetic factors
play a role in inter-individual variation in levels of these iron
biomarkers. For example, hemochromatosis (HFE) variants are
associated with hereditary hemochromatosis, which can lead to
iron overload and damage to the liver and other organs (4).
Iron biomarkers show significant heritability, apart from her-
editary hemochromatosis (5). Single nucleotide polymorphisms
(SNPs) associated with iron trait variation have been reported in
European populations, where 11 loci associated with iron traits
were detected in a recent meta-analysis (6). Other genome-wide
association study (GWAS) analyses have been conducted in
African Americans (7) and East Asian men (8). Analysis of candi-
date variants in 233 Hispanic/Latino individuals replicated sev-
eral associations for the TF locus and TIBC found in other
populations (9). However, there has been no published genome-
wide analysis of iron traits in Hispanic/Latino populations.
Analysis of iron trait genetics in diverse populations is import-
ant, as there are known differences between ancestry groups. For
example, hereditary hemochromatosis is more common in indi-
viduals of European versus African or Hispanic ancestry (10).
There may also be differences in iron levels between population
groups, such as lower SAT but higher serum ferritin among
African Americans (compared with Europeans) (11). These differ-
ences could be due in part to genetic factors.
A connection between metabolic disorders—such as diabetes,
insulin resistance and fatty liver disease—and iron overload due
to hereditary hemochromatosis (12), thalassemia with hyper-
transfusion (13) or other conditions (14) is well-established.
Moreover, excess iron is epidemiologically associated with a
higher incidence of type 2 diabetes (T2D) (reviewed in 15,16). For
example, elevated serum ferritin levels were associated with
roughly a 4-fold increase in the odds of newly diagnosed diabetes
in the National Health and Nutrition Education Survey study (17).
A few studies have examined genetic factors that influence both
iron stores and diabetes risk (18,19), yielding various results.
Further work is needed. Better understanding of the genetic
underpinnings of iron homeostasis may help elucidate new path-
ways and connections between iron metabolism and chronic dis-
eases, including diabetes.
Here we report a GWAS analysis of iron traits in the Hispanic
Community Health Study/Study of Latinos (HCHS/SOL), to iden-
tify potential novel factors involved in iron regulation. We also
aimed to assess the role of previously identified iron trait vari-
ants in a Hispanic/Latino population. A third goal was to exam-
ine the overlap between iron-related loci and risk factors for
diabetes or impaired glycemic control. Our results confirm
known associations of iron traits with eight loci and potentially
identify a novel iron locus.
Results
Outcomemeasures
Demographic characteristics and levels of iron measures are in
Table 1, for the entire sample and for females (n ¼ 7241) and
males (n ¼ 5122) separately. Histograms for the distribution of
iron measures in the cohort are in Supplementary Material, Fig.
S1. Average age in the cohort was 46.1 years (SD 13.9). The aver-
age body mass index (BMI) was 29.8 (SD 6.1, median 29), indicat-
ing that a high percentage of the cohort was overweight or
obese. Prevalence of diabetes was 19.6%, which is higher than
the estimated prevalence in the entire HCHS/SOL cohort (16.9%,
n ¼ 16 385) (20). Serum iron levels correlated positively with fer-
ritin (r ¼ 0.420) and SAT (r ¼ 0.939) and negatively with TIBC
(r¼0.125) (Supplementary Material, Table S1).
Primary GWAS analysis
SNPs representing the previously reported TF, HFE, fatty acid
desaturase 2 (FADS2)/ myelin regulatory factor (MYRF) and
transmembrane protease, serine 6 (TMPRSS6) loci were
associated with one or more iron traits at genome-wide signifi-
cance (P < 5  108) (Table 2). An additional novel variant at the
protein phosphatase 1, regulatory subunit 3B (PPP1R3B) locus
was nearly genome-wide significant for TIBC (P ¼ 7.44  108).
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All genome-wide significant variants listed in Table 2 were dir-
ectly genotyped or had an imputation r2 > 0.95. Manhattan and
quantile–quantile (Q–Q) plots and results for all SNPs with P < 1
 106 for each iron trait are in the supplement (serum iron:
Supplementary Material, Fig. S2, Table S2; TIBC: Supplementary
Material, Fig. S3, Table S3; SAT: Supplementary Material, Figure
S4, Table S4; ferritin: Supplementary Material, Fig. S5, Table S5).
Results for each locus are detailed below.
The TF locus. Variants in the TF locus reached genome-wide
significance for TIBC and SAT (Supplementary Material, Fig.
S6). Conditional analysis of the TF locus showed five distinct
genome-wide significant signals for TIBC, represented by
non-coding variants rs6762719, rs2692666, rs1130459,
rs1405023 and rs4637289. Two of these variants are in modest
LD with rs6762719 in HCHS/SOL (rs1405023, r2 ¼ 0.43;
rs1130459, r2 ¼ 0.22) and two are not (rs2692666 and
rs4637289, r2 < 0.1). Variant rs1130459 was not associated
with TIBC in the primary analysis (b-value¼0.0006, S.E. ¼
0.018, P ¼ 0.971), but became significant when conditioned on
variants rs6762719 and rs2692666 (b-value ¼ 0.269; S.E. ¼
0.018, P ¼ 8.68  1051 after conditioning). Our top TF SNP
(rs6762719) is in very high LD with the lead variant at TF re-
ported in Europeans (rs8177240; r2 ¼ 0.98 in the 1000 Genomes
European reference panel) (6). Variant rs1405023 shows mod-
est LD with rs8177179 (r2 ¼ 0.42 in 1000 Genomes Europeans),
which was identified by conditional analysis at the TF locus in
Europeans (6). Conditional analysis showed a single inde-
pendent signal at TF for SAT (rs6762719).
Table 2. SNPs significantly associated with one or more iron traits
Chr SNP Position Nearest gene Annotation Effect allele EAF Alternate allele Iron traita b-value P-value
3 rs4637289 133458497 TF intronic A 0.874 G Ferritin 0.003 0.625
Serum iron 0.036 0.296
TIBC 0.255 1.8  1024
SAT 0.058 0.005
3 rs2692666 133478354 TF intronic G 0.969 A Ferritin 0.000 0.978
Serum iron 0.306 2.57  106
TIBC 1.376 8.06  10190
SAT 0.240 1.72  109
3 rs6762719 133480817 TF intronic A 0.602 G Ferritin 0.010 0.038
Serum iron 0.081 5.55  104
TIBC 0.676 0 (<1.0  10306)
SAT 0.149 4.05  1025
3 rs1405023 133481128 TF intronic T 0.614 C Ferritin 0.014 0.003
Serum iron 0.003 0.900
TIBC 0.152 4.50  1018
SAT 0.038 0.009
6 rs1799945 26091179 HFEb His63Asp C 0.883 G Ferritin 0.043 1.13  109
Serum iron 0.365 3.65  1026
TIBC 0.218 7.37  1018
SAT 0.274 2.21  1038
6 rs1800562 26093141 HFEb,c Cys282Tyr G 0.982 A Ferritin 0.027 0.109
Serum iron 0.349 2.26  105
TIBC 0.522 3.81  1018
SAT 0.371 2.10  1013
8 rs4841132 9183596 PPP1R3B intergenic A 0.182 G Ferritin 0.007 0.220
Serum iron 0.040 0.177
TIBC 0.116 7.44  108
SAT 0.053 0.003
11 rs174529 61543961 FADS2/MYRF intronic (MYRF) T 0.465 C Ferritin 0.009 0.073
Serum iron 0.026 0.283
TIBC 0.099 4.51 108
SAT 0.045 0.002
22 rs855791 37462936 TMPRSS6d,e Val736Ala A 0.439 G Ferritin 0.023 5.83  107
Serum iron 0.322 4.61  1046
TIBC 0.056 9.92  104
SAT 0.202 2.73  1048
aA log base 10 transformation was used for ferritin, and square root transformation was used for serum iron, TIBC, and transferrin saturation.
bThe minor alleles for both of these HFE variants are associated with higher iron levels [represented by a G nucleotide on the þ strand at rs1799945 (and aspartate at
residue 63) and an A nucleotide on the þ strand at rs1800562 (and tyrosine at residue 282)].
cTransferrin saturation HFE variant rs79220007 is an LD proxy for coding variant rs1800562 p.Cys282Tyr (r2 ¼ 0.98). Variant rs79220007 was thus not included.
dFerritin lead TMPRSS6 variant rs760719 is in high LD (r2 ¼ 0.79) with coding variant rs855791, which is known to be associated with iron traits (6), and its effect was
non-significant when conditioned on rs855791. Variant rs760719 was thus not included.
eThe valine allele is listed as the reference allele in NCBI databases (2321A > G; Val736Ala, with an A nucleotide on the – strand at rs855791), but alanine more likely
represents the ancestral allele, because it is conserved across multiple species (gorilla, mouse, rat, chicken) (21).
Gene symbols and abbreviations: TF, transferrin; HFE, hereditary hemochromatosis; PPP1R3B, protein phosphatase 1, regulatory subunit 3B; MYRF, myelin regulatory fac-
tor; FADS2, fatty acid desaturase 2; TMPRSS6, transmembrane protease, serine 6; EAF, effect allele frequency; TIBC, total iron-inding capacity; SAT, transferrin saturation.
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The HFE locus. The HFE locus reached genome-wide significance
for all tested iron traits (Supplementary Material, Fig. 7). For serum
iron and ferritin, a single signal was revealed by conditional ana-
lysis (rs1799945, p.His63Asp). For TIBC and SAT, conditional ana-
lysis showed two independent signals at the HFE locus, represented
by rs1799945 (p.His63Asp) and rs1800562 (p.Cys282Tyr) (which are
in very low LD, r2¼ 0.002). These coding HFE variants are associated
with hereditary hemochromatosis in homozygotes and compound
heterozygotes (hemochromatosis, type 1, OMIM 235200). The se-
cond independent signal for SAT was led by rs79220007, which is in
very strong linkage disequilibrium (LD) with rs1800562 (r2¼ 0.98).
The FADS2/MYRF locus. A single intron variant in MYRF was
associated with TIBC (P ¼ 4.51  108; Supplementary Material,
Fig. S8). The variant is in strong LD with an intron variant in
FADS2 (rs174577, r2 ¼ 0.76 in 1000 Genomes Europeans), which
was associated with TF among Europeans (6).
The TMPRSS6 locus. There was a single independent signal at
TMPRSS6 (Supplementary Material, Fig. S9), which was con-
firmed by conditional analysis. The signal was represented by
lead variant rs855791 (p.Val736Ala) for serum iron and SAT, and
by lead variant rs760719 for ferritin. Variants rs760719 and
rs855791 are in strong LD (r2 ¼ 0.79).
The PPP1R3B locus. A novel association involving a variant
near the PPP1R3B locus and TIBC showed near genome-wide
significance (rs4841132, b ¼0.116, P ¼ 7.44  108;
Supplementary Material, Fig. S10).
Additional signals. A low-frequency intergenic variant on
chromosome 1 was associated with TIBC (rs78455250,
b¼0.621, P ¼ 3.83  108; Supplementary Material, Fig. S11). A
low-frequency intronic variant on chromosome 5 was associ-
ated with SAT (rs2442120, P ¼ 4.92  108; Supplementary
Material, Fig. S12). However, the association became non-
significant when conditioned on the TF, HFE and TMPRSS6 loci,
and replication was not pursued.
Replication of novel signals
The newly identified PPP1R3B variant was nominally associated
with TF levels (which are linearly related to TIBC values) in the
European meta-analysis (b¼0.0577, P ¼ 0.0014; personal com-
munication with Dr Benyamin) (6). A significant association was
not observed in the Jackson Heart Study, although the esti-
mated association was in the same direction (b¼2.162, P ¼
0.246) (7). Variant rs4841132 was most common in the admixed
American populations in 1000 Genomes Phase 1 (19% minor al-
lele frequency, compared with 10% in African, 8% in European
and 1% in Asian populations).
Table 3. Generalization of iron related variants identified in European populations by Benyamin et al. (6) in the HCHS/SOL
Effect allele Benyamin et al. HCHS/SOL
rsID Chr Position Nearest gene Trait EAF b-value P-value EAF b-value r-valuea
rs744653 2 190378750 WDR75–SLC40A1 T Transferrinb 0.854 0.068 1.35  1011 0.887 0.016 0.16
Log_Ferritin 0.854 –0.089 8.37  1019 0.887 –0.002 1
rs8177240 3 133477701 TF T Serum iron 0.669 –0.066 6.65  1020 0.613 –0.022 4.33  1024
Transferrin 0.669 –0.38 8.43  10610 0.613 –0.241 4.20  10295
Saturation 0.669 0.1 7.24  1038 0.613 0.061 3.48  10223
rs9990333 3 195827205 TFRC T Transferrin 0.46 –0.051 1.95  1013 0.331 –0.009 0.24
rs1800562 6 26093141 HFE (Cys282Tyr) A Serum iron 0.067 0.328 2.72  1097 0.018 0.096 1.20  1025
Transferrin 0.067 –0.479 8.90  10196 0.018 –0.189 1.97  10216
Saturation 0.067 0.577 2.19  10270 0.018 0.172 7.81  10216
Log_Ferritin 0.067 0.204 1.54  1038 0.018 0.033 0.33
rs1799945 6 26091179 HFE (His63Asp) C Serum iron 0.85 –0.189 1.10  1081 0.883 –0.094 4.03  10227
Transferrin 0.85 0.114 9.36  1030 0.883 0.081 6.33  10217
Saturation 0.85 –0.231 5.13  10109 0.883 –0.120 1.51  10241
Log_Ferritin 0.85 –0.065 1.71  1010 0.883 –0.053 3.59  1025
rs7385804 7 100235970 TFR2 A Serum iron 0.621 0.064 1.36  1018 0.704 0.025 1.14  1024
Saturation 0.621 0.054 6.07  1012 0.704 0.018 7.72  1023
rs4921915 8 18272466 NAT2 A Transferrin 0.782 0.079 7.05  1019 0.669 0.027 9.17  1025
rs651007 9 136153875 ABO T Log_Ferritin 0.202 –0.05 1.31  108 0.164 –0.032 1.84  1023
rs6486121 11 13355770 ARNTL T Transferrin 0.631 –0.046 3.89  1010 0.515 –0.012 0.09
rs174577 11 61604814 FADS2 A Transferrin 0.33 0.062 2.28  1017 0.551 0.035 6.76  1027
rs411988 17 56709034 TEX14 A Log_Ferritin 0.564 –0.044 1.59  1010 0.407 –0.009 1
rs855791 22 37462936 TMPRSS6 A Serum iron 0.446 –0.181 1.32  10139 0.439 –0.082 9.41  10247
(Val736Ala) Transferrin 0.446 0.044 1.98  109 0.439 0.020 2.63  1023
Saturation 0.446 –0.19 6.41  10137 0.439 –0.087 1.30  10250
Log_Ferritin 0.446 –0.055 1.38  1014 0.439 –0.029 6.99  1026
Reported b-values are from the generalization analysis, which used the same phenotype transformations as in Benyamin et al. (6)
aSignificant r-values are bolded (r<0.05).
bTIBC values were used to generalize transferrin results.
Gene symbols and abbreviations: WDR75–SLC40A1, WD repeat domain 75—solute carrier family 40 (iron-regulated transporter), member 1 (also known as ferroportin);
TF, transferrin; TFRC, transferrin receptor; HFE, hereditary hemochromatosis; TFR2, transferrin receptor 2; NAT2, N-acetyltransferase 2 (arylamine N-acetyltransferase);
ABO, ABO blood group; ARNTL, aryl hydrocarbon receptor nuclear translocator like; FADS2, fatty acid desaturase 2; TEX14, testis expressed 14; TMPRSS6, transmembrane
protease, serine 6; EAF, effect allele frequency; TIBC, total iron-binding capacity.
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As mentioned earlier, a variant on chromosome 1 was also
associated with TIBC (rs78455250). The variant had a low minor
allele frequency in HCHS/SOL (0.2%). The minor allele frequency
was higher in the Jackson Heart Study (2.3%), but association with
TIBC was in the opposite direction and non-significant (b ¼ 1.451,
P ¼ 0.762). This variant was not observed in European 1000
Genomes participants, so replication in Europeans was not at-
tempted. The variant is not considered further here.
Sensitivity analysis excluding individuals with iron
deficiency
Excluding individuals with iron deficiency reduced effect sizes
for TF and SAT loci in the European meta-analysis (6).
Therefore, we excluded individuals with iron deficiency, as a
sensitivity analysis for our HCHS/SOL GWAS. Most associations
(28/36; Supplementary Material, Table S6) became more signifi-
cant, despite the reduced sample size. For example, the associ-
ation of rs4841132 (near PPP1R3B) with TIBC became stronger
and genome-wide significant (original model, b¼0.116, P ¼
7.44  108, n ¼ 12 585; excluding iron deficient individuals,
b¼0.121, P ¼ 4.78  109, n ¼ 11 614).
Moreover, an additional 213 SNPs had genome-wide signifi-
cant effects after excluding iron deficient individuals (1397
genome-wide significant SNPs, Supplementary Material, Table
S7). All but 14 of these variants were in previously recognized
loci in HCHS/SOL. For example, associations of SNPs in TF with
serum iron strengthened to genome-wide significance levels
(lead variant rs2692696, P ¼ 5.11  109; Supplementary
Material, Fig. S13.a). However, a new genome-wide significant
association of SNPs in ABO blood group (ABO) with ferritin was
observed, led by intron variant rs657152 (b ¼ 0.025, P ¼ 1.94 
108; Supplementary Material, Fig. S13.b). Variant rs657152 is in
modest LD (r2 ¼ 0.4 in the 1000 Genomes Europeans) with
rs651007, a variant downstream of ABO that was associated
with ferritin levels in European populations (6) and generalized
to HCHS/SOL (r-value ¼ 1.84  103; Table 3). Two imputed vari-
ants not at previously identified loci were also associated with
serum iron (rs144628729 and rs181143083).
Generalization of previously identified GWAS signals in
HCHS/SOL
In the largest European meta-analysis, Benyamin et al. detected
associations between iron traits and 11 loci [HFE (two independ-
ent variants), solute carrier family 40 (iron-regulated trans-
porter), member 1 (SLC40A1), TF, transferrin receptor 2 (TFR2),
transferrin receptor (TFRC), TMPRSS6, ABO, aryl hydrocarbon
receptor nuclear translocator like (ARNTL), FADS2, N-acetyl-
transferase 2 (arylamine N-acetyltransferase) (NAT2), testis
expressed 14 (TEX14)] (6). We investigated all variants for all
iron traits, because several were associated with multiple iron
traits. Eight of the twelve variants from Benyamin et al. general-
ized to HCHS/SOL, with 5 generalizing for multiple iron traits
(Table 3; Supplementary Material, Fig. S14.a–d).
There were a number of loci with different associations with
iron traits in HCHS/SOL, compared with the European meta-
analysis. For example, rs1800562 in HFE was highly significant
for ferritin in the discovery cohort, but it did not generalize
and had a much lower estimated effect in HCHS/SOL
(Supplementary Material, Fig. S14.d). This variant had strong as-
sociations in HCHS/SOL with SAT, TIBC and serum iron, so lack
of association with ferritin may not be simply due to lack of
power. Additionally, rs744653 near the WDR75–SLC40A1 locus
was associated with both ferritin and TF in Benyamin et al., but
it was not associated with any iron trait in HCHS/SOL. Variants
rs9990333 (near TFRC), rs6486121 (in ARNTL) and rs411988 (in
TEX14) also showed no evidence of generalization in HCHS/SOL.
Finally, some variants that did generalize had confidence inter-
vals that did not overlap with previously reported b-values. For
example, HFE variant rs1800562 and TMPRSS6 variant rs85579
consistently had more modest estimated b-values in HCHS/SOL,
suggesting differences in effect sizes between populations.
The largest analysis of iron-related traits in African
Americans found four loci associated with ferritin and TIBC (7).
Two of these generalized to HCHS/SOL (Table 4; Supplementary
Material, Fig. S15.a and b). The estimated confidence intervals
for the non-generalized loci are consistent with no association
(rather than lack of power; Supplementary Material, Fig. 15.b).
One variant was identified in an East Asian GWAS of ferritin,
but the variant did not generalize to HCHS/SOL (rs5742933 on
chromosome 2 (8), P ¼ 0.122; not included in Tables 3 and 4).
Associations of iron loci with glycemic traits
We tested the lead variants from each iron-associated locus for
associations with glycemic traits: rs6762719 for TF, rs1799945 for
HFE, rs4841132 for PPP1R3B, rs174529 for FADS2/MYRF and
rs855791 for TMPRSS6 (Table 5). All effect alleles in Table 5 cor-
respond to the iron raising allele, for easier interpretation of the
b-values.
The PPP1R3B locus. The PPP1R3B variant was associated with
higher fasting glucose (P ¼ 7.70  107), insulin levels (P ¼ 4.79 
106) and homeostasis model assessment of insulin resistance
(HOMA-IR), a correlated, calculated measure of insulin resist-
ance (P ¼ 4.98  107). Adjustment for TIBC did not attenuate as-
sociations of PPP1R3B with glycemic traits, with little change in
the P-values (insulin resistance, P ¼ 1.02  108; fasting glucose,
P ¼ 5.05  107; fasting insulin, P ¼ 1.3  107) or b-values
(Supplementary Material, Table S8.a).
Other loci. The iron-raising alleles at TMPRSS6 (rs855791, P ¼
8.66  1010) and HFE (rs1799945, P ¼ 2.44  105) were associ-
ated with lower HbA1c levels in HCHS/SOL. Adjustment for iron
measures attenuated, but did not eliminate, the associations
with HbA1c (Supplementary Material, Table S8.b). Adjustment
for SAT most strongly attenuated the HFE association (P ¼
0.0166) and the TMPRSS6 association (P ¼ 2.40  105). Iron is
therefore at least one of the likely mediators of the HbA1c
associations.
An unweighted genetic risk score (GRS) based on the five
sentinel SNPs was associated with lower HbA1c levels (P ¼ 5.64
 106) and was more nominally associated with higher
levels of fasting glucose (P ¼ 0.004) (multiple comparisons
threshold, P < 0.004; Table 5). These five sentinel SNPs together
explain only a small percentage of the residual variance in iron
traits (9.6% of TIBC, 1.8% of SAT, 1.6% of serum iron, <0.1% of
ferritin), after adjusting for the potential confounders in our
SNP association models (such as age, sex, heritage group and
kinship). We also derived a 10-variant, unweighted GRS, based
on the 5 sentinel SNPs plus 5 variants that generalized to HCHS/
SOL. Single variant associations for the five generalized SNPs
with glycemic traits are shown in Supplementary Material,
Table S9. The 10-variant GRS was associated with lower odds
for diabetes (P ¼ 1.43  103) and lower HbA1c (P ¼ 1.11  1015;
Table 5). For both the 5- and 10-variant scores, the association
with HbA1c became non-significant when signals at HFE and
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TMPRSS6 (and GRB2 associated binding protein 3 (GAB3) for the
10-variant GRS) were removed (P > 0.1). A more nominal associ-
ation (P ¼ 0.004) of the 5-variant score with higher fasting glu-
cose was attenuated when the signal at PPP1R3B was removed
(P > 0.32).
Replication in other studies. We examined associations of our
iron-related loci with T2D and related traits in published GWAS
meta-analyses. No variant was associated with T2D status. The
iron-raising allele of the PPP1R3B variant was associated with
higher fasting glucose (P ¼ 3.35  109) and higher fasting insu-
lin (P ¼ 1.71  109), as well as more nominally with higher insu-
lin resistance (P ¼ 0.001), as in HCHS/SOL (Supplementary
Material, Table S10). SNPs at the loci for TMPRSS6 (rs855791, P ¼
2.74  1014) and HFE (rs1799945, P ¼ 1.43  104) were associ-
ated with lower HbA1c levels. MYRF/FADS2 proxy vari-
ant rs174577 was strongly associated with higher fasting glucose
(P ¼ 1.54  1010) and more modestly with lower b-cell function
(P ¼ 0.0001). The closely linked FADS1 gene is a recognized
Table 4. Generalization of iron related variants identified in African American populations by Li et al. (7) to the HCHS/SOL
Li et al. HCHS/SOL
rsID Chr Position Nearest gene Effect allele Trait EAF b-value P-value EAF b-value r-valuea
rs8177253 3 133480192 TF T Total iron-binding capacity 0.24 19.86 1.80  1047 0.398 24.07 1.63  10250
rs115923437 6 22678302 HDGFL1 C Total iron-binding capacity 0.06 14.84 1.10  108 0.008 1.21 1
rs16951289 16 79790621 MAF-DYNLRB2 T Total iron-binding capacity 0.07 13.38 2.00  108 0.012 0.75 1
rs141555380 X 153906012 GAB3 T Log_Ferritin 0.14 0.17 1.10  108 0.023 0.10 3.20  1024
Reported b-values are from the generalization analysis, which used the same phenotype transformations as in Li et al. (7).
Gene symbols and abbreviations: TF, transferrin; HDGFL1, hepatoma derived growth factor-like 1; MAF-DYNLRB2, MAF bZIP transcription factor—dynein, light chain,
roadblock-type 2; GAB3, GRB2 associated binding protein 3; EAF, effect allele frequency.
aSignificant r-values are bolded (r<0.05).
Table 5. Associations of iron-related loci with glycemic traits
rsID rs6762719 rs1799945 rs4841132 rs174529 rs855791
Chromosome 3 6 8 11 22
Position 133480817 26091179 9183596 61543961 37462936 GRSc
Gene TF HFE PPP1R3B FADS2/MYRF TMPRSS6 5-variant 10-variant
Iron raising allele A G A T G
Diabetes Odds ratio .95 0.97 1.00 1.03 0.92 0.99 0.99
P-valuea 0.225 0.622 0.983 0.554 0.060 0.075 1.43  1023
n 7746 7746 7745 7746 7746 7745 7745
2-h postload glucose b-valueb 0.063 1.367 1.652 0.537 0.691 0.458 0.388
P-value 0.885 0.035 0.002 0.229 0.103 0.035 0.021
n 9622 9622 9621 9622 9622 9621 9621
Fasting glucose b-value 0.132 0.115 0.706 0.266 0.209 0.167 0.092
P-value 0.257 0.499 7.70  1027 0.027 0.063 0.004 0.040
n 10065 10065 10064 10065 10065 10064 10064
Fasting insulin b-value 0.001 0.006 0.020 0.004 0.001 0.003 0.001
P-value 0.831 0.268 4.79  1026 0.323 0.824 0.129 0.371
n 10053 10053 10052 10053 10053 10052 10052
HbA1c b-value 0.006 0.031 0.009 0.013 0.030 0.012 0.016
P value 0.235 2.44  1025 0.173 0.013 8.66  10210 5.64  1026 1.11  10215
n 9636 9636 9635 9636 9636 9635 9635
HOMA-B b-value 0.002 0.005 0.012 0.008 0.001 0.0002 0.00003
P-value 0.510 0.365 0.009 0.026 0.742 0.893 0.982
n 10045 10045 10044 10045 10045 10044 10044
HOMA-IR b-value 0.000 0.006 0.023 0.002 0.002 0.004 0.002
P-value 0.977 0.256 4.98  1027 0.543 0.649 0.062 0.248
n 10052 10052 10051 10052 10052 10051 10051
aSignificant P-values are bolded (P < 0.001 for single variant tests, P < 0.004 for the GRS).
bAll b-values are calculated with respect to the indicated iron raising alleles.
cThe GRSs are unweighted and based on either the five sentinel SNPs (5-variant) or the five sentinel SNPs plus 5 generalized SNPs from reported genome-wide associ-
ation studies (10-variant). The GRSs are calculated with respect to the iron raising alleles.
dA log base 10 transformation was used for fasting insulin, HOMA-IR and HOMA-B. Other glycemic trait measures were not transformed.
Gene symbols and abbreviations: TF, transferrin; HFE, hereditary hemochromatosis; PPP1R3B, protein phosphatase 1, regulatory subunit 3B; FADS2, fatty acid desatur-
ase 2; MYRF, myelin regulatory factor; TMPRSS6, transmembrane protease, serine 6; HbA1c, glycated hemoglobin; HOMA-B, homeostasis model assessment of b-cell
function; HOMA-IR, homeostasis model assessment of insulin resistance.
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genome-wide significant locus for fasting glucose and homeosta-
sis model assessment of b-cell function (HOMA-B) (22,23).
Discussion
Associations of variants with iron traits
In the HCHS/SOL cohort, we found genome-wide significant as-
sociations of iron traits with four previously known loci (TF,
HFE, FADS2/MYRF, TMPRSS6) and identified a potential novel
iron locus (PPP1R3B).
PPP1R3B is a subunit of the serine/threonine phosphatase,
protein phosphatase-1 (PP1). PPP1R3B (originally called GL) tar-
gets PP1 to glycogen synthase in the liver, regulating glycogen
storage. PPP1R3B is also highly expressed in human skeletal
muscle (24). To our knowledge, there is no direct link between
PPP1R3B and iron metabolism, and this variant has not been
previously associated with iron traits. The observed association
was replicated for TF in results from a European meta-analysis
(6; Benyamin, personal communication). However, the PPP1R3B
association did not replicate in African Americans from the
Jackson Heart Study—though the estimated association was in
the same direction (7). The lack of replication could be due to
differences in effect allele frequencies between populations, be-
cause the identified variant has a higher effect allele frequency
in admixed American populations in the 1000 Genomes refer-
ence panel (compared with European, African, or Asian popula-
tions). This higher frequency may have facilitated detection of
the novel association with TIBC.
The SNP associated with TIBC (rs4841132) lies within a non-
coding RNA locus (LOC157273)—roughly 200 kilobases away
from the PPP1R3B gene. Recent siRNA knockdown experiments
suggest that LOC157273, a hepatocyte specific transcript, regu-
lates PPP1R3B mRNA levels (25). Moreover, LOC157273/PPP1R3B
locus variants have been associated with a variety of cardiome-
tabolic phenotypes, including levels of LDL, HDL, total choles-
terol (26), C-reactive protein (27), blood lactate (28), fat
accumulation in the liver measured by computed tomography
(29), fasting blood glucose (23), including levels during preg-
nancy (30), fasting blood insulin (23) and liver enzymes (31). The
potential pleiotropic effects of PPP1R3B or LOC157273 on these
multiple cardiometabolic phenotypes warrant further study.
The impact of the locus on iron traits in particular should be
further assessed in diverse populations.
Generalization of previously observed variants
We attempted to generalize variant-phenotype associations
observed in the largest GWAS analyses of European and African
American populations (7). Eight of the twelve variants from the
European meta-analysis generalized to HCHS/SOL for at least one
iron trait. Two of the four variants from the African American
study generalized. Several variants, including a variant near
GAB3 in African Americans and variants near ABO, NAT2 and
FADS2 in European Americans, have not been previously con-
firmed in an independent study. Therefore, generalization to
HCHS/SOL provides important validation of these results.
Other variants did not generalize to HCHS/SOL, including
SNPs at WDR75–SLC40A1, TFRC, ARNTL and TEX14 from the
European meta-analysis and hepatoma derived growth factor-
like 1 (HDGFL1) and MAF bZIP transcription factor – dynein, light
chain, roadblock-type 2 (MAF-DYNLRB2) from the African
American meta-analysis. Lack of generalization may be due to
different effect sizes in the original study population versus
HCHS/SOL. Alternatively, lack of power may have led to reduced
precision in effect size estimation. For the variants from the
European meta-analysis that did not generalize, the estimated
directions of effects were consistent with those in HCHS/SOL
(Supplementary Material, Figs S14.b and d) (6). For the two vari-
ants from the African American meta-analysis that did not gen-
eralize, the estimated direction of effect in HCHS/SOL was the
same as in the original study for rs16951289, but not for
rs115923437 (Supplementary Material, Fig. S15.b). Both variants
had a much smaller effect allele frequency in HCHS/SOL than in
the original analysis by Li et al. (7). Differences in allele frequen-
cies are less extreme for the non-generalized variants from the
European GWAS. Specifically, no non-generalized variant had a
minor allele frequency <10% in either cohort. However, several
variants do have lower minor allele frequencies in HCHS/SOL
than in the Benyamin et al. meta-analysis, which may modestly
impact power (e.g. rs9990333). Other possible reasons for lack of
generalization include differences in causal variants or haplo-
type structure between populations, gene–environment inter-
actions and heterogeneity in environmental exposures between
populations (such as iron in the diet), sampling error in either
the original study or HCHS/SOL (such that the tested subpopula-
tion does not represent the larger population), and unaccounted
for sources of variance.
Apart from variants that did not generalize, some variants
showed evidence of different effect sizes in HCHS/SOL. For ex-
ample, HFE variant rs1800562 (p.Cys282Tyr) consistently
showed a smaller effect size in HCHS/SOL than in the European
meta-analysis – likely due to the higher prevalence of hereditary
hemochromatosis and p.Cys282Tyr homozygotes in Europeans
(10). The TMPRSS6 (rs855791) and TF (rs8177240) variants also
had significantly lower estimated effect sizes in HCHS/SOL. The
reasons for these population differences in effect size are un-
clear. Differences in non-genetic factors between studies, such
as socioeconomic status, demographic traits and diet, may play
a role. However, our results generally support the role of known
iron trait loci in a Hispanic/Latino population, suggesting that
these alleles are derived from a common founder population.
Associations of variants with iron and diabetes related
traits
Excess iron is epidemiologically associated with an increased
incidence of T2D (15,16). Many mechanisms for this link have
been proposed. Although iron is needed for b-cell function and
survival, free iron gives rise to reactive oxygen species in these
metabolically active cells. Excess iron may also influence glu-
cose utilization in hepatic and adipose tissue. As a possible
mechanism, high iron (like high oxygen) decreases levels of
hypoxia inducible factors, which in turn reduces levels of glu-
cose transporters and insulin secretion. Iron also may impact
circadian rhythms in the liver (altering hepatic gluconeogene-
sis) or mediate epigenetic effects, such as histone demethyla-
tion (15,16). Therefore, associations of iron loci with diabetes
and glycemic traits are of interest. Five sentinel SNPs were se-
lected from among the iron related loci found in HCHS/SOL (TF,
HFE, PPP1R3B, FADS2/MYRF and TMPRSS6). We hypothesized
that alleles associated with raised iron levels may also be asso-
ciated with increased diabetes risk.
PPP1R3B. The TIBC lowering and SAT raising allele for
PPP1R3B variant rs4841132 was associated with higher levels of
fasting glucose, fasting insulin and insulin resistance in HCHS/
SOL. In earlier GWAS analyses, rs4841132 was associated with
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higher fasting insulin and fasting glucose levels (23), including
levels during pregnancy (30). As discussed earlier, PPP1R3B regu-
lates glycogen storage in the liver, providing a potential mech-
anistic link to glucose homeostasis (32). Adjustment for TIBC
did not attenuate associations of PPP1R3B with fasting glucose,
fasting insulin, or insulin resistance. Therefore, iron is not a
likely mediator of the observed diabetes-related effects of
rs4841132. PPP1R3B or LOC157273 may instead have pleiotropic
effects on both iron and glycemic phenotypes. An effect of a
PPP1R3B variant (rs9987289) on CRP levels in a previous study
was similarly not attenuated by adjustment for HDL, LDL or
total cholesterol (all traits associated with rs9987289). Lack of at-
tenuation is compatible with pleiotropic effects on these traits
(33). A number of iron loci identified here or in previous studies
have been associated with lipid traits by the Global Lipids
Genetics Consortium (PPP1R3B, FADS2, ABO, HFE, NAT2) (26),
suggesting there may be shared determinants of lipids and iron
that could have relevance to diabetes.
TMPRSS6 and HFE. Iron-raising alleles for TMPRSS6 (rs855791,
P ¼ 8.66  1010) and HFE (rs1799945, P ¼ 2.44  105) were asso-
ciated with lower HbA1c levels. Iron attenuated these associ-
ations in HCHS/SOL. In support of our results, TMPRSS6
(rs855791) and HFE (rs1800562) variants were associated with
lower HbA1c levels in a meta-analysis of nondiabetic adults of
European descent (34). Red blood cell production involves iron,
so we performed look-ups for our five sentinel variants with
eight hematological traits in a previous HCHS/SOL GWAS
(Supplementary Material, Table S11). Iron-raising variants of
HFE and TMPRSS6 were associated with higher hemoglobin (P 
8.20  108), mean corpuscular volume (MCV) (P  8.49  106),
and mean corpuscular hemoglobin (MCH) (P  2.39  1011),
along with other red blood cell traits—similar to results from a
European meta-analysis (35). Iron-raising alleles of TMPRSS6 (at
rs855791) and HFE (at rs1799945 and rs1800562) may therefore
contribute to increased hemoglobin levels (35)—resulting in a
lower calculated percentage of HbA1c. Alternatively, iron may
impact the rate of hemoglobin glycation. Iron-deficiency
anemia has been associated with spuriously high HbA1c,
compared with other markers of glycemia. Moreover, iron re-
placement therapy lowers HbA1c and raises total hemoglobin
levels in diabetic and non-diabetic individuals (36–38).
Malondialdehyde, which is elevated in patients with iron defi-
ciency anemia (38), can increase hemoglobin glycation in vitro,
providing a possible mechanism (39). Further assessment of the
role of genetic factors that influence iron traits on HbA1c as a
screening tool for diabetes is warranted.
Genetic risk scores. Overall, we found few compelling associ-
ations with either a 5- or 10-variant GRS, except for an associ-
ation with lower HbA1c—likely due to effects on red cells,
instead of glucose.
No association with increased risk for diabetes was
observed. We did see nominal associations with quantitative
glycemic traits indicative of higher diabetes risk, e.g. higher
fasting glucose.
Our results are consistent with the limited evidence for a
link between iron variants and diabetes risk in previous studies.
A GRS based on six iron variants was modestly associated with
increased odds for diabetes among men in the Health
Professionals Follow-Up Study (18). However, the association
was not observed in women and was attenuated by BMI adjust-
ment. In a Chinese cohort, the iron lowering TMPRSS6 rs855791
A variant (with valine at position 736) was associated with lower
plasma ferritin levels (b ¼ 0.061, P ¼ 0.002) and with modestly
lower risk for T2D (OR 0.801, 95% CI 0.65–0.98; P ¼ 0.031) (19).
Strengths and limitations
Our study represents the first GWAS of iron indices in a
Hispanic/Latino cohort. Additional strengths are analyses of the
impact of iron deficiency on SNP-iron trait associations (which
were generally stronger when iron deficient individuals were
excluded) and a formal generalization analysis of GWAS loci
identified in European and African American populations. We
hypothesize that excluding individuals with iron deficiency re-
duces heterogeneity due to non-genetic factors, such as dietary
iron, blood loss (among premenopausal women), regional back-
ground and socioeconomic status. Limitations include lack of a
sample size large enough for a more comprehensive evaluation
of variants and inability to further explore reasons for lack of
generalization. We were also unable to further clarify potential
reasons for significant differences in effect sizes between popu-
lations in the generalization analysis. The low variance in iron
traits explained by our five sentinel SNPs limits our power to de-
tect modest associations between the genetic determinants of
iron levels (as assessed by a GRS) and diabetes or related traits.
Identification of more variants associated with iron traits in
larger Hispanic/Latino cohorts would improve power. We thus
cannot exclude a modest effect of iron related variants on dia-
betes related traits. Lack of differentiation between type 1 and
type 2 diabetes (in a small percentage of cases) in HCHS/SOL
may also impact our ability to detect associations with diabetes
case/control status.
Future directions
Important future studies of iron genetics may include trans-
ethnic meta-analyses and evaluations of iron biomarkers in
additional Hispanic/Latino cohorts, which may help identify
other iron-associated variants. Assessment of iron variants in
multi-ethnic cohorts may also be useful for identifying reasons
for lack of generalization between populations or different vari-
ant effect sizes. Large scale sex-stratified analyses may also be
an important future direction, as women generally have lower
body iron stores (particularly premenopausal women).
However, we observed no heterogeneity in effects between men
and women for genome-wide significant loci in HCHS/SOL (by
Cochran Q testing; results not shown). The lack of compelling
associations of iron related SNPs with glycemic traits and dia-
betes in HCHS/SOL should also be explored in additional ances-
try groups, because a relationship between iron traits and
diabetes may vary between populations.
Summary
Our results show the generalization of previously reported asso-
ciations between iron traits and TF, HFE, FADS2/MYRF, TMPRSS6,
TFR2, NAT2, ABO and GAB3 to a Hispanic/Latino population. We
identified a potential novel iron locus, PPP1R3B, where lead vari-
ant rs4841132 was associated with lower TIBC levels. The asso-
ciation was replicated in summary statistics from a previous
European meta-analysis and warrants further exploration. The
PPP1R3B variant was associated with higher fasting glucose and
insulin levels, and higher insulin resistance, but these effects
were unrelated to TIBC. None of the other iron variants was
associated with increased risk for diabetes, either individually
or as part of a GRS. Further research is needed to explore poten-
tial links between the genetic determinants of iron and glucose
homeostasis.
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Materials and Methods
HCHS/SOL
The HCHS/SOL cohort began in 2006 as a prospective study of
Hispanic/Latino populations in the USA. (40–42). From 2008 to
2011, 16 415 adults were recruited from a random sample of
households in four communities (the Bronx, Chicago, Miami,
and San Diego). Each Field Center recruited >4000 participants
from diverse socioeconomic groups. Most participants self-
identified as having Cuban, Dominican, Puerto Rican, Mexican,
Central American or South American heritage. A total of 12 803
individuals consented for genotyping. The study protocol was
approved by the institutional review boards of all collaborating
institutions, and written informed consent was obtained for all
participants. Here we use data collected from study participants
at their first clinic visit.
Outcomemeasures
Tests used to characterize body iron stores included serum iron,
TIBC and ferritin. Serum iron was measured on a Roche
Modular P chemistry analyzer using a ferrozine reagent (Roche
Diagnostics, Indianapolis, IN). Unsaturated iron binding cap-
acity (UIBC) was assayed on the same sample, and TIBC was cal-
culated by the formula: TIBC ¼ serum iron þ UIBC. Ferritin was
measured in serum with Roche reagents on a Cobas 6000
Analyzer (Roche Diagnostics), using a particle enhanced immu-
noturbidimetric assay. SAT levels were calculated by the for-
mula: SAT ¼ serum iron/TIBC  100.
Diabetes mellitus status was defined using American
Diabetes Association criteria (43). Individuals with a level of
fasting (>8 h) glucose 126 mg/dl, non-fasting (8 h) glucose or
2-h postload glucose from an oral glucose tolerance test (OGTT)
200 mg/dl, HbA1c 6.5%, or who used a diabetes medication
were defined as diabetes cases. Individuals with levels of fasting
glucose <100 mg/dl, 2-h post-load glucose from an OGTT
<140 mg/dl, and HbA1c <5.6% were defined as diabetes controls.
Individuals with intermediate values, which may indicate an
increased risk for diabetes, were not included as controls. There
were 2499 cases and 5247 controls defined by these criteria. The
prevalence of diabetes among 18–29-year olds was only 2.6% in
the entire HCHS/SOL cohort (20). We estimate that the preva-
lence of T2D among diabetic individuals in our analysis is
roughly >95% (with a small percentage of type 1 diabetes cases
likely included), based on the low diabetes prevalence in
younger HCHS/SOL participants. Diabetes cases were excluded
from analyses of glycemic traits, including 2-h postload glucose
from an OGTT, fasting glucose and insulin, HbA1c and the
homeostasis model assessments of insulin resistance and b-cell
function (HOMA-IR and HOMA-B).
Genotyping and imputation
Genotyping and imputation protocols have been described pre-
viously in (44). Genotyping was performed by Illumina
Microarray Services with a custom array [>2.5 million SNPs
from the HumanOmni2.5-8v1-1 array and 150 000 custom
SNPs; Illumina (San Diego, CA)]. Genotype data were cleaned
and quality checked centrally at Illumina Microarray Services,
LA Biomed, and the University of Washington, which heads the
HCHS/SOL Genetic Analysis Center. SHAPEIT2 was used for pre-
phasing (45), and imputation to the 1000 Genomes full, cosmo-
politan phase 1 version 1 reference panel was completed using
IMPUTE2 (46). There were >25.5 million imputed genotypes, for
a total of 27.7 million tested SNPs. We excluded variants with
low minor allele counts (<30) and low imputation quality (<0.3)
from all results shown.
Primary GWAS analysis
GWAS analyses of iron traits were performed in all individuals
with genomic and iron trait data (12 375 participants for ferritin;
12 580 for serum iron; 12 586 for TIBC; and 12 589 for SAT).
Extreme outliers were excluded (ferritin > 10 000 ng/ml; serum
iron >270 mg/dl; TIBC > 580 mg/dl). Participants with malignant
tumors of the blood or lymph system or bone cancer (n ¼ 28), high
immature granulocyte counts (n ¼ 2), end-stage renal disease (n ¼
46) or pregnancy at the time of iron trait measurement (n ¼ 8)
were excluded, as were participants on chemotherapy (n ¼ 54).
To approximate a normal distribution, a log base 10 trans-
formation was used for ferritin, and square root transformation
was used for serum iron, TIBC and SAT. We used a mixed model
approach implemented in the GENESIS package (GENetic
EStimation and Inference in Structured samples) in R (version
2.0.1), which can account for population structure/ancestry in
related individuals (47), to assess SNP associations with iron-
related traits. A detailed description of the GWAS analysis
methods for HCHS/SOL has been previously published in (48).
SNP associations were adjusted for sex, age, cigarette use, heri-
tage group (Mexican, Central American, South American,
Cuban, Dominican, Puerto Rican), sampling design, kinship,
household, census block, recruitment center and the first five
ancestry principal components. Individuals who were outliers
for ancestry principal components were excluded (n ¼ 56).
Chromosome X was analyzed separately, with adjustment for
chromosome X specific eigenvectors. The HCHS/SOL Genetic
Analysis Center tracks all genome-wide analyses performed
(see Supplementary Material, Table S12 for analysis identifica-
tion numbers). Genomic inflation was assessed with Q–Q plots.
Variants with P < 106 were annotated with ANNOVAR (49) and
included in the online Supplementary Tables. We defined asso-
ciations with P < 5  108 as genome-wide significant.
LocusZoom plots (50) were used to visualize genome-wide sig-
nificant loci, with LD for these plots calculated from HCHS/SOL
genotype data. HaploReg v4.1 was used to explore the potential
functional significance of identified lead variants (51).
To study the possibility that an associated locus may contain
more than one distinct association signal, conditional analyses
were done for each genome-wide significant locus using
GENESIS. The lead variant was included as a covariate, with se-
quential inclusion of the next lead variant until no genome-
wide significant signals remained within 1 Mb.
Replication of novel signals
We attempted to replicate the associations for two novel
genome-wide significant signals (for TIBC) by accessing sum-
mary statistics from previous GWAS analyses for these variants.
We contacted the lead authors of a meta-analysis of European
populations (48 972 subjects from 11 discovery and eight repli-
cation cohorts) (6) and a GWAS of African Americans in the
Jackson Heart Study (2347 subjects from a population-based
study from the Jackson, MS, metropolitan area) (7) to obtain
these results. In Europeans, results for TF were used to replicate
TIBC associations, because TF and TIBC levels are linearly
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related (52,53). An association was considered replicated if the
variant had the same direction of association and P < 0.05.
Sensitivity analysis excluding individuals with iron
deficiency
We also repeated our genome-wide analyses for ferritin, TIBC,
serum iron and SAT after excluding individuals with iron defi-
ciency (defined by ferritin values below the reference range: <25
mg/l for men and <15 mg/l for women).
Generalization analysis
We tested loci identified in GWAS analyses in African American
and European populations for generalization in HCHS/SOL.
Following Sofer et al. (54), the generalization null hypothesis
takes into account both the discovery study and the generaliz-
ing study (here HCHS/SOL). The generalization null hypothesis
is rejected if evidence for SNP-phenotype association exists in
both studies, with the same direction of association. As a first
step, we estimated SNP-phenotype associations in HCHS/SOL
using the same phenotype transformations that were used in
the original study. Next, we tested the generalization null hy-
pothesis, while controlling for the false discovery rate (FDR) due
to multiple testing, by calculating FDR-controlling directional r-
values (54) for all SNP associations. We concluded that an asso-
ciation was generalized if the SNP-phenotype association had
an r-value < 0.05. All 12 variants from the European meta-
analysis (6) were tested for generalization for all four iron traits
in HCHS/SOL. However, the four variants from the African
American GWAS were tested on only the significant trait from
the original report, because association results were not avail-
able for all iron traits (7).
Analysis of iron variants with glycemic traits
We chose a single lead variant from each identified iron locus to
test for associations with diabetes and six glycemic traits [2-h
postload glucose from an OGTT, fasting glucose and insulin,
HbA1c, HOMA-IR (insulin resistance) and HOMA-B (b-cell func-
tion)]. Five sentinel SNPs were assessed in this way, represent-
ing the most significant SNP at all genome-wide significant loci
and the near genome-wide significant locus at PPP1R3B.
Associations with P < 0.001 were accepted as significant, based
on a correction factor of 1/35 (for testing five SNPs and seven
traits).
To increase power, we derived an unweighted GRS based on
the five sentinel SNPs (calculated with respect to iron raising al-
leles). Sample sizes for GRS analyses depended on the number
of participants with no missing genotypes for any of the vari-
ants. We also derived a 10-variant, unweighted GRS, based on
the 5 sentinel SNPs plus 5 previously reported variants (6,7) that
generalized to HCHS/SOL (rs1800562 in HFE, rs7385804 in TFR2,
rs4921915 near NAT2, rs651007 near ABO, rs141555380 in GAB3).
The five-variant GRS focused on loci that were genome-wide
significant in HCHS/SOL. The 10-variant GRS more comprehen-
sively examined all independent loci that showed evidence
for influencing iron traits in HCHS/SOL. None of the
generalized variants was in significant LD with the five sentinel
SNPs (r2 < 0.1). Associations with P < 0.004 were considered sig-
nificant for GRS analyses, based on a correction factor of 1/14
(for 2 GRS values and 7 traits).
We additionally assessed effects of our five iron-related loci
on T2D status in a published trans-ethnic GWAS meta-analysis
of European, East Asian, South Asian, Mexican and Mexican
American ancestry individuals (55). Examination of previous
European ancestry GWAS results was also performed for gly-
cemic traits, including 2-hour post-load glucose from OGTT
data (56), fasting glucose and insulin (unadjusted for BMI) (23),
HbA1c (34), HOMA-IR and HOMA-B (22) in nondiabetic individ-
uals. Data on glycemic traits were contributed by MAGIC inves-
tigators (downloaded from www.magicinvestigators.org). Data
were not available from these GWAS meta-analyses for
rs174529 (FADS2/MYRF) or rs6762719 (TF), so proxy SNPs were
selected. We chose to analyze the lead European variants at
these loci (rs8177240 for TF and rs174577 for FADS2), because
both generalized to HCHS/SOL and were strongly associated
with our iron traits of interest.
Look-up of HCHS/SOL hematological trait results
We performed look-ups for our five sentinel iron variants in a
previous HCHS/SOL GWAS on hematological traits (red blood
cell count, hemoglobin, hematocrit, MCV, MCH, mean corpuscu-
lar hemoglobin concentration, red blood cell distribution width,
platelet count). All complete blood counts were assessed at the
central laboratory at the University of Minnesota Medical
Center, Fairview, in Minneapolis. We used a multiple testing
corrected significance threshold of P < 0.001.
Supplementary Material
Supplementary Material is available at HMG online.
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